Companies › ARJ Medical
2 active drug programs in 3 registered trials: 3 Phase 3; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Comparator Breath Test | – | Phase 3 | Helicobacter Pylori Infection | – |
| PyloPlus Urea Breath Test System Non-radioactive 13C-urea breath test for H. pylori detection | – | Phase 3 | Helicobacter Pylori; Helicobacter Pylori Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05276557 | PyloPlus Urea Breath Test System | Phase 3 | Helicobacter Pylori | Infectious disease | Jun 2023 |
| NCT05681689 | PyloPlus Urea Breath Test System | Phase 3 | Helicobacter Pylori Infection | Infectious disease | Jun 2023 |
| NCT05681689 | Comparator Breath Test | Phase 3 | Helicobacter Pylori Infection | Infectious disease | Jun 2023 |
No annotated target.
–
National Vaccine and Serum Institute, China NPO Petrovax Xiamen Innovax Biotech MAXVAX Biotechnology Limited Liability Company Catalysis
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.